01. Doctor Overview
Dr. Tobias Peikert is a pulmonologist and critical care specialist currently working at the Mayo Clinic in Minnesota. Throughout his career, Dr. Peikert has been heavily involved in research for a number of diseases, including mesothelioma. He has helped author numerous medical studies around the rare cancer, investigating new treatments for all types of cancer, surgical reduction for epithelioid mesothelioma, particular genes that have been associated with mesothelioma, as well as investigating new modes of immunotherapy
Dr. Peikert has also held prominent roles in the efforts to research mesothelioma, previously serving as the Elected Chair of the Scientific Advisory Board of the Mesothelioma Applied Research Foundation (MARF) from 2016 – 2018, as well as acting as Chair of the Task Force’s Ethics Subcommittee IASLC Mesothelioma Task Force during the same time period.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Pulmonology
Other Interests & Specialties: Lung cancer, mesothelioma, cancer immunology, immunotherapy, ANCA associated vasculitis and fibrosing mediastinitis.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Critical Care Medicine, American Board of Internal Medicine Certification in Pulmonary Disease, V Foundation Scholar, Annenberg Career Development Award, Eagles Cancer Fellowship Award, Burgher Family Fellowship in Pulmonary Disease, former Elected Chair of the Scientific Advisory Board of the Mesothelioma Applied Research Foundation
Education & Experience:
- Fellowship in Pulmonary and Critical Care at Mayo Clinic College of Medicine
- Post Doctoral Fellowship in Department of Cancer Biology/ Department of Pulmonary Medicine at Cleveland Clinic Foundation
- Residency in Internal Medicine at Cleveland Clinic Foundation
- Medical Degree from Martin-Luther-University Halle-Wittenberg
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology. November 2018;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. Mayo Clinic Proceedings. August 2018;93(8):1026-1033. doi: 10.1016/j.mayocp.2018.01.032
Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal of Thoracic Oncology. September 2018;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011